within Pharmacolibrary.Drugs.ATC.A;

model A10BG04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.98,
    Cl             = 8e-06,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0136,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0019166666666666668,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BG04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lobeglitazone is a thiazolidinedione class antidiabetic medication that acts as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It is used to improve glycemic control in adults with type 2 diabetes mellitus. Lobeglitazone has been approved for use in countries such as South Korea.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult male volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Park, MK, et al., &amp; Lim, KS (2014). Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects. <i>Clinical drug investigation</i> 34(7) 467–474. DOI:<a href=\"https://doi.org/10.1007/s40261-014-0197-y\">10.1007/s40261-014-0197-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24802657/\">https://pubmed.ncbi.nlm.nih.gov/24802657</a></p></li><li><p>Sil Oh, E, et al., &amp; Park, MS (2014). Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. <i>Clinical therapeutics</i> 36(7) 1064–1071. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2014.05.064\">10.1016/j.clinthera.2014.05.064</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25047497/\">https://pubmed.ncbi.nlm.nih.gov/25047497</a></p></li><li><p>Moon, SJ, et al., &amp; Kim, MG (2020). An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men. <i>Clinical therapeutics</i> 42(6) 1047–1057. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2020.04.005\">10.1016/j.clinthera.2020.04.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32362346/\">https://pubmed.ncbi.nlm.nih.gov/32362346</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BG04;
